{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:26:33Z","timestamp":1788395193450,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006662","name":"Ardabil University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.ARUMS.REC.1401.191"],"award-info":[{"award-number":["IR.ARUMS.REC.1401.191"]}],"id":[{"id":"10.13039\/501100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.compbiomed.2025.109784","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:04:21Z","timestamp":1738627461000},"page":"109784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Computer-aided design of imatinib derivatives: Overcoming drug-resistance in chronic myeloid leukemia"],"prefix":"10.1016","volume":"187","author":[{"given":"S.","family":"Gholizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-2497","authenticated-orcid":false,"given":"N.","family":"Razzaghi-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.compbiomed.2025.109784_bib1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.compbiomed.2025.109784_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s43042-023-00411-3","article-title":"The importance of personalized medicine in chronic myeloid leukemia management: a narrative review","volume":"24","author":"Zaker","year":"2023","journal-title":"Egypt J Med Hum Genet"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109784_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109784_bib4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Zhong","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.compbiomed.2025.109784_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.compbiomed.2025.109784_bib6","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","article-title":"Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in frst-line treatment of chronic myeloid leukemia","volume":"100","author":"Gugliotta","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.compbiomed.2025.109784_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1389557518666181017124854","article-title":"Chronic myeloid leukemia: existing therapeutic options and strategies to overcome drug resistance","volume":"19","author":"Singh","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.109784_bib8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.compbiomed.2025.109784_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","volume":"24","author":"Meenakshi Sundaram","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"32","key":"10.1016\/j.compbiomed.2025.109784_bib10","doi-asserted-by":"crossref","first-page":"19221","DOI":"10.1073\/pnas.1919221117","article-title":"Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase","volume":"117","author":"Hoemberger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.compbiomed.2025.109784_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol.\/Oncol. Clin."},{"issue":"5531","key":"10.1016\/j.compbiomed.2025.109784_bib12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"5682","key":"10.1016\/j.compbiomed.2025.109784_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.compbiomed.2025.109784_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.compbiomed.2025.109784_bib15","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5\u20136","key":"10.1016\/j.compbiomed.2025.109784_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The ins and outs of BCR-ABL inhibition","volume":"3","author":"Premkumar Reddy","year":"2012","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.compbiomed.2025.109784_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: a review of efficacy and safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.compbiomed.2025.109784_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.compbiomed.2025.109784_bib19","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2025.109784_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109784_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"issue":"7280","key":"10.1016\/j.compbiomed.2025.109784_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting BCR-ABL by combining allosteric with ATP binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109784_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109784_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of BCR-ABL mutations on patients with chronic myeloid leukemia","volume":"10","author":"Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.compbiomed.2025.109784_bib25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fchem.2019.00873","article-title":"In silico methods for design of kinase inhibitors as anticancer drugs","volume":"7","author":"Gagic","year":"2020","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109784_bib26","first-page":"153","article-title":"In silico analysis and docking of imatinib derivatives targeting BCR-ABL oncoprotein for chronic myeloid leukemia","volume":"5","author":"Sravani","year":"2012","journal-title":"Asian J Research Chem"},{"issue":"10","key":"10.1016\/j.compbiomed.2025.109784_bib27","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1080\/07391102.2015.1110046","article-title":"In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study","volume":"34","author":"Kumar","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2025.109784_bib28","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5486","key":"10.1016\/j.compbiomed.2025.109784_bib29","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.compbiomed.2025.109784_bib30","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.compbiomed.2025.109784_bib31","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109784_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1179\/1607845412Y.0000000050","article-title":"Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance","volume":"18","author":"Chahardouli","year":"2013","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.compbiomed.2025.109784_bib33","first-page":"412","article-title":"T315I - a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia","volume":"5","author":"Kaleem","year":"2024","journal-title":"Adv Lab Med"},{"issue":"11","key":"10.1016\/j.compbiomed.2025.109784_bib34","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jmb.2019.04.009","article-title":"Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated?","volume":"431","author":"Ittisoponpisan","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"D1","key":"10.1016\/j.compbiomed.2025.109784_bib35","doi-asserted-by":"crossref","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic. Acids.Adv. Lab. Med. Res."},{"key":"10.1016\/j.compbiomed.2025.109784_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.109784_bib37","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2025.109784_bib38","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"17","author":"Sanner","year":"1999","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.compbiomed.2025.109784_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107204","article-title":"Gefitinib derivatives and drug-resistance: a perspective from molecular dynamics simulations","volume":"163","author":"Ahmadi","year":"2023","journal-title":"Comput. Biol. Med."},{"issue":"W1","key":"10.1016\/j.compbiomed.2025.109784_bib40","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.compbiomed.2025.109784_bib41","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"Plip 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.109784_bib42","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109784_bib43","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/ct200196m","article-title":"An automated force field topology builder (ATB) and repository: version 1.0","volume":"7","author":"Malde","year":"2011","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.compbiomed.2025.109784_bib44","series-title":"Intermolecular Forces","first-page":"331","article-title":"Interaction models for water in relation to protein hydration","author":"Berendsen","year":"1981"},{"key":"10.1016\/j.compbiomed.2025.109784_bib45","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109784_bib46","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.compbiomed.2025.109784_bib47","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2025.109784_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1386207013330661","article-title":"The linear interaction energy method for predicting ligand binding free energies","volume":"4","author":"\u00c5qvist","year":"2001","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.compbiomed.2025.109784_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/7.3.385","article-title":"A new method for predicting binding affinity in computer-aided drug design","volume":"7","author":"Aqvist","year":"1994","journal-title":"Protein Eng."},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109784_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.compbiomed.2025.109784_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of BCR-ABL inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.compbiomed.2025.109784_bib52","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bmcl.2005.11.042","article-title":"Design and synthesis of 3-substituted benzamide derivatives as BCR-ABL kinase inhibitors","volume":"16","author":"Asaki","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.compbiomed.2025.109784_bib53","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual BCR-ABL\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109784_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jcb.30359","article-title":"Effects of the pathological E200K mutation on human prion protein: a computational screening and molecular dynamics approach","volume":"124","author":"Gharemirshamloo","year":"2023","journal-title":"J. Cell. Biochem."},{"issue":"21","key":"10.1016\/j.compbiomed.2025.109784_bib55","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.3390\/molecules28217266","article-title":"In silico molecular docking and dynamics simulation analysis of potential histone lysine methyl transferase inhibitors for managing \u03b2-thalassemia","volume":"28","author":"Ravikumar","year":"2023","journal-title":"Molecules"},{"issue":"W1","key":"10.1016\/j.compbiomed.2025.109784_bib56","doi-asserted-by":"crossref","first-page":"W477","DOI":"10.1093\/nar\/gkz456","article-title":"2StrucCompare: a webserver for visualizing small but noteworthy differences between protein tertiary structures through interrogation of the secondary structure content","volume":"47","author":"Drew","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109784_bib57","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in BCR-ABL tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109784_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201700533","article-title":"Dual drug targeting of mutant Bcr-Abl induces inactive conformation: new strategy for the treatment of chronic myeloid leukemia and overcoming monotherapy Resistance","volume":"15","author":"El Rashedy","year":"2018","journal-title":"Chem. Biodivers."},{"issue":"3","key":"10.1016\/j.compbiomed.2025.109784_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/j100785a001","article-title":"van der Waals volumes and Radii","volume":"68","author":"Bondi","year":"1964","journal-title":"J. Phys. Chem."},{"issue":"16","key":"10.1016\/j.compbiomed.2025.109784_bib60","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/jp110373f","article-title":"Conformational relaxation and water penetration coupled to ionization of internal groups in proteins","volume":"115","author":"Damjanovi\u0107","year":"2011","journal-title":"J. Phys. Chem. A"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109784_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcb.30354","article-title":"An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer","volume":"124","author":"R","year":"2023","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.compbiomed.2025.109784_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.compbiomed.2025.109784_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"Pt 1","key":"10.1016\/j.compbiomed.2025.109784_bib64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482525001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:28:59Z","timestamp":1777350539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482525001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":64,"alternative-id":["S0010482525001349"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109784","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computer-aided design of imatinib derivatives: Overcoming drug-resistance in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109784"}}